Programmed cell death protein 1

BeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeline Assets

Retrieved on: 
Monday, October 16, 2023

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the presentation of promising new data showcasing BeiGene’s robust, science-driven solid tumor portfolio of commercialized and pipeline medicines at the European Society for Medical Oncology (ESMO) Congress 2023.

Key Points: 
  • BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the presentation of promising new data showcasing BeiGene’s robust, science-driven solid tumor portfolio of commercialized and pipeline medicines at the European Society for Medical Oncology (ESMO) Congress 2023.
  • “Tislelizumab is the cornerstone of BeiGene’s diverse pipeline of pan-solid tumor programs for the next wave of immuno-oncology targets.
  • Additionally, the U.S. Food and Drug Administration (FDA) recently accepted for review a Biologics License Application for tislelizumab as a first-line treatment for patients with unresectable, recurrent, locally advanced, or metastatic ESCC.
  • Long-term Follow-up of a Phase 2 Study of Tislelizumab (TIS) Monotherapy in Patients (pts) With Previously Treated, Locally Advanced, Unresectable or Metastatic Microsatellite Instability-high (MSI-H) or Mismatch Repair-deficient (dMMR) Solid Tumors.

Andira Advances Lead Cannabinoid Compositions for Metastatic Breast Cancer through a Collaborative Research Agreement with Canada Research Chair in Oncology Dr. Karla Williams at the University of British Columbia

Retrieved on: 
Wednesday, March 22, 2023

The endeavor aims to validate the pharmacologic effects of the lead compounds in the estrogen receptor positive (ER+) form of metastatic breast cancer.

Key Points: 
  • The endeavor aims to validate the pharmacologic effects of the lead compounds in the estrogen receptor positive (ER+) form of metastatic breast cancer.
  • "While treatments for many forms of breast cancer have improved considerably, that is not the case for metastatic breast cancer.
  • Dr. Karla Williams serves as the Canada Research Chair in Oncology at the Canadian Institutes of Health Research (CIHR).
  • Williams' research aims to improve breast cancer patient outcomes through the development of novel strategies to detect and treat breast cancer.

Stella Diagnostics and Mayo Clinic to Present Data on the Utility of the STLA101 Test for Esophageal Cancer Staging at the 2022 AGA Digestive Disease Week Conference

Retrieved on: 
Wednesday, May 11, 2022

This presentation highlights that the markers in the STLA101 panel can inform medical providers if their patients esophageal cancer is intramucosal or intramuscular.

Key Points: 
  • This presentation highlights that the markers in the STLA101 panel can inform medical providers if their patients esophageal cancer is intramucosal or intramuscular.
  • A large percentage of histologic specimens of esophageal tumors do not show sufficient tissue depth to distinguish intramucosal from invasive carcinomas.
  • Here, we show that molecular diagnostics via mass spectrometry may aid in characterizing the depth of invasion, when paired with histology.
  • Dr. Hartley is a board-certified gastrointestinal pathologist and principal investigator of Stella Diagnostics Collaborative Research Agreement with the Mayo Clinic.

Stella Diagnostics Announces Leadership Changes: Dr. Joe Abdo Assumes a New Role as Chief Scientific Officer, and Director David Seaburg is Appointed Chief Executive Officer

Retrieved on: 
Friday, April 22, 2022

In order to successfully implement new processes, products, and business strategies, Dr. Joe Abdo will assume the newly created position of Chief Scientific Officer, and David Seaburg, who is currently a member of Stella Diagnostics Board of Directors, has been appointed Chief Executive Officer.

Key Points: 
  • In order to successfully implement new processes, products, and business strategies, Dr. Joe Abdo will assume the newly created position of Chief Scientific Officer, and David Seaburg, who is currently a member of Stella Diagnostics Board of Directors, has been appointed Chief Executive Officer.
  • Since coming on board as a Director, David has been a key member of our leadership team.
  • David Seaburg brings extensive global commercialization and finance skills from executive leadership roles in his distinguished career on Wall Street.
  • David Seaburg, Chief Executive Officer of Stella Diagnostics, said, I am honored to have this opportunity to work with Joe and the Board to lead Stella Diagnostics through its next phase of growth and development.

Cancer Advances, Inc. Announces Publication, "Gastrin Vaccine Alone and in Combination with an Immune Checkpoint Antibody Inhibits Growth and Metastases of Gastric Cancer" in Frontiers in Oncology

Retrieved on: 
Monday, December 6, 2021

Tumor growth was significantly slower than controls in PAS-treated mice, and tumor growth rate was decreased even more in combination-treated mice.

Key Points: 
  • Tumor growth was significantly slower than controls in PAS-treated mice, and tumor growth rate was decreased even more in combination-treated mice.
  • There were no metastases in any of the mice treated with PAS either alone or in combination with PD-1 Ab.
  • Polyclonal Antibody Stimulator (PAS) vaccine is an immunomodulator potentially applicable in multiple cancer types including gastric, pancreatic, and colorectal.
  • Cancer Advances exclusively owns PAS and is funding and managing all aspects of the PAS gastrin vaccine program.

Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Triple-Negative Breast Cancer (TNBC)

Retrieved on: 
Thursday, October 28, 2021

The expanded use of PD-L1 IHC 22C3 pharmDx strengthens the ability of pathologists to identify patients who may be eligible for treatment with KEYTRUDA.

Key Points: 
  • The expanded use of PD-L1 IHC 22C3 pharmDx strengthens the ability of pathologists to identify patients who may be eligible for treatment with KEYTRUDA.
  • "This indication expansion of PD-L1 IHC 22C3 pharmDx in TNBC will allow physicians in Europe access to critical information to qualify even more patients who could benefit from these treatments.
  • This further demonstrates Agilents role as a leader in developing companion diagnostics for targeted therapies."
  • PD-L1 IHC 22C3 pharmDx was developed by Agilent as a companion diagnostic for KEYTRUDA in partnership with Merck.

Researchers Discover Previously Unknown Role of BioAegis’ Therapeutic Gelsolin as Key Signaling Protein Vital for Regulating Immune Cell Inflammatory Response

Retrieved on: 
Tuesday, September 28, 2021

NORTH BRUNSWICK, New Jersey, Sept. 28, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory, and degenerative diseases based on a portfolio built around gelsolin technology, announced that a previously unknown role of gelsolin in a signaling system in macrophages was published in the Journal of Immunology.

Key Points: 
  • The paper, Quorum Sensing by Gelsolin Regulates Programmed Cell Death 4 Expression and a Density-Dependent Phenotype in Macrophages , was recently published in the Journal of Immunology.
  • The study shows that plasma gelsolin (pGSN) controls this process by regulating the expression of a protein known as Programmed Cell Death 4 (PCD4).
  • Gelsolin, a naturally occurring human protein that is abundant in healthy individuals, is a key component of the bodys innate immune system.
  • BioAegis will also have US biologics exclusivity and has recently filed new IP in areas of unmet need.

Coherus BioSciences Reports Second Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress

Retrieved on: 
Thursday, August 5, 2021

ET

Key Points: 
  • ET
    REDWOOD CITY, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today reported financial results for the quarter ended June 30, 2021.
  • In April 2021, the Company received $50 millionfrom Junshi Biosciences acquisition of 2,491,988 shares of Coherus stock.
  • Cost of goods sold (COGS), increased to $16.7 million in the second quarter of 2021 as compared to $10.1 million in second quarter of 2020.
  • Our results for the quarter ended June 30, 2021 are not necessarily indicative of our operating results for any future periods.

Iovance Biotherapeutics Reports Second Quarter and First Half 2021 Financial Results and Corporate Updates

Retrieved on: 
Thursday, August 5, 2021

SAN CARLOS, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported second quarter 2021 financial results and corporate updates.

Key Points: 
  • SAN CARLOS, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported second quarter 2021 financial results and corporate updates.
  • Research and development expenses were$62.1 millionfor the second quarter endedJune 30, 2021, an increase of$12.8 millioncompared to$49.3 millionfor the second quarter endedJune 30, 2020.
  • General and administrative expenses were$19.3 millionfor the second quarter endedJune 30, 2021, an increase of$5.0 millioncompared to$14.4 millionfor the second quarter endedJune 30, 2020.
  • Iovance will host a conference call today at4:30 p.m. ETto discuss the second quarter 2021 financial results and corporate updates.

Purple Biotech Provides Corporate Update and Reports First Half 2021 Financial Results

Retrieved on: 
Thursday, August 5, 2021

REHOVOT, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (Purple Biotech, or the Company) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today provided a corporate update and announced financial results for the six months ended June 30, 2021.

Key Points: 
  • REHOVOT, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (Purple Biotech, or the Company) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today provided a corporate update and announced financial results for the six months ended June 30, 2021.
  • We achieved significant progress in the advancement of our promising oncology pipeline during the first half of 2021, said Isaac Israel, Chief Executive Officer of Purple Biotech.
  • Initial results from the first dose level cohort showed that NT219 was well-tolerated with minimal serious adverse events.
  • These are factors that we believe could cause our actual results to differ materially from expected results.